This week, Dr. Kevin Cross from Instem is presenting at the 2022 Genetic Toxicology Association meeting on recent progress in predicting N-nitrosamine carcinogenicity potency. The presentation outlines progress over the last year and provides an update on different collaborative working groups, including a recently announced EMA-MutAmind project funded by the European Medicine’s Agency and led by Fraunhofer ITEM that includes Instem as a partner.1

The presentation provides an overview of the different reaction mechanisms involved in N-nitrosamines mutagenicity and compares Nitrosamine Drug Substance-Related Impurities (NDSRIs) against historical information on tested nitrosamines. This includes an assessment of historical Ames negative studies that have historically tested positive for rodent carcinogenicity. Recent testing of these ‘false negatives’ are presented and discussed relative to experimental protocols used and structural classes where issues occur, allowing for more directed future assessments of nitrosamines.

The presentation is available to view:

<View presentation>

Please get in touch if we can help answer any questions on this important topic (Glenn Myatt,


  1. Instem Awarded EMA Research Grant.

Published by Glenn Myatt

Glenn J. Myatt is the co-founder of Leadscope and currently Senior Vice President, In Silico & Translational Science Solutions at Instem with over 30 years’ experience in computational chemistry/toxicology. He holds a Bachelor of Science degree in Computing, a Master of Science degree in Artificial Intelligence and a Ph.D. in Chemoinformatics. He has published 37 papers, 11 book chapters and three books.